DEVELOPMENT OF ANT-VIRAL HEPATITIS THERAPY WITH BACULOVIRAL VECTORS CARRYING CYTOKINE GENES.

丙型肝炎病毒和乙型肝炎病毒是慢性肝炎、肝硬变和肝细胞癌的主要病原体。目前，干扰素主要用于治疗由这两种药物引起的慢性肝炎。然而，其疗效是有限的，开发新的抗病毒药物是必不可少的。我们试图制造携带干扰素-γ的重组杆状病毒，以便将来应用于人类慢性肝炎的治疗。利用重组杆状病毒在人肝癌细胞株中高效表达了干扰素-γ基因。在产生乙肝病毒颗粒的2.2.15细胞系中，重组杆状病毒感染显著抑制了病毒的复制。到目前为止，给小鼠接种杆状病毒还没有产生基因，目前正在进行进一步的试验。这种产生干扰素-γ的重组杆状病毒系统是未来治疗难以治愈的慢性肝炎的一种有希望的设备。

Hepatitis C virus (HCV) and hepatitis B virus (HBV) are the major causative agents responsible for the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Currently, interferons are mainly used for the treatment of chronic hepatitis which is induced by these two agents. However, its efficacy is limited and development of new anti-viral agents is indispensable. We attempted to make recombinant baculoviruses carrying the interferon-γ for the future application to human chronic hepatitis treatment. Interferon-γ gene was efficiently expressed in HepG2 cells using the recombinant baculovirus. In 2.2.l5 cell lines which produces HBV particles, replication of HBV was significantly inhibited by infection with recombinant baculovirus. Inoculation of mice with baculovirus has not led to the production of genes so far, and further trials are now underway. This recombinant baculovirus system which produces interferon-γ is a promising device for future treatment of hardly curable chronic hepatitis.